Abstract Library

#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lepage C

Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,

Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,

#1207 A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the occurrence of hyperparathyroidism, pituitary adenomas and duodeno-pancreatic neuroendocrine tumours (NETs). Germline mutations of the MEN1 gene are identified in up to 87% of MEN1 families and 82% of isolated MEN1 cases.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Iacovazzo D

Authors: Iacovazzo D, Piacentini S, Lugli F, Bianchi A, Gabrovska P,

Keywords: MEN1, mutation, gastric carcinoid,